Side Effect Management•Evidence reviewed September 2026•11 min read

GLP-1 Gallbladder Stones: What Every Ozempic, Wegovy, Mounjaro, and Zepbound User Should Know About Gallstone Risk

GLP-1 medications increase gallstone risk by approximately 37% according to a meta-analysis of 76 clinical trials with 103,371 patients. Here is what the evidence says about gallbladder disease on semaglutide and tirzepatide, which drugs carry the highest risk, symptoms to watch for, and evidence-based strategies to reduce your risk.

Written by OffRamp GLP-1 Editorial TeamReviewed by OffRamp GLP-1 Research Team

Gallbladder disease is one of the most under-discussed side effects of GLP-1 therapy, but the evidence is consistent and actionable

Questions like "Can Ozempic cause gallstones?" and "Does Wegovy increase gallbladder risk?" are among the most common concerns users raise. The short answer: yes, but the risk is dose-dependent, drug-specific, and partially modifiable through dietary choices.

If you have been on a GLP-1 medication and started having right-sided abdominal pain, nausea after meals, or discomfort that seems to come and go, you are not imagining it. Gallbladder-related symptoms are one of the more common side effects of GLP-1 therapy, though they receive far less attention than nausea or constipation.

The data is consistent across multiple large-scale analyses. A landmark 2022 systematic review and meta-analysis by He et al. in JAMA Internal Medicine pooled 76 randomized clinical trials involving 103,371 patients and found that GLP-1 receptor agonist use was associated with a 37% increased relative risk of gallbladder or biliary diseases. The risk was substantially higher in weight-loss trials (RR 2.29) and at higher doses (RR 1.56). A 2025 FAERS database analysis of over 4,000 reported gallbladder events confirmed the signal in real-world pharmacovigilance data, with semaglutide showing an ROR of 5.74 and liraglutide showing an ROR of 6.75 for cholecystitis and cholelithiasis.

This guide explains what the evidence actually says, which drugs carry the highest risk, what gallbladder symptoms look like on GLP-1s, and, most importantly, what you can do about it. The goal is not to scare anyone off treatment. The absolute risk remains modest for most people. But understanding the risk allows you to manage it proactively rather than discover it in an emergency room.

Key highlights

  • •A meta-analysis of 76 RCTs found GLP-1 use is associated with a 37% higher relative risk of gallbladder or biliary disease, the absolute risk is approximately 27 additional events per 10,000 patients per year.
  • •Risk is significantly higher in weight-loss trials (RR 2.29), at higher doses (RR 1.56), and with longer duration of use (RR 1.40 for >26 weeks).
  • •Liraglutide carries the highest gallbladder risk among GLP-1 drugs (RR 1.79). Semaglutide at doses ≥1.0mg also shows elevated risk (RR 1.58). Oral semaglutide may not increase risk.
  • •The primary mechanism is not just rapid weight loss, GLP-1 drugs suppress cholecystokinin (CCK), reducing gallbladder contraction and causing bile stasis, which promotes cholesterol crystallization and stone formation.

How common is gallbladder disease on GLP-1 medications?

The most comprehensive analysis of gallbladder risk with GLP-1 drugs is the He et al. 2022 systematic review and meta-analysis published in JAMA Internal Medicine. It pooled 76 randomized controlled trials with 103,371 participants and found that randomization to any GLP-1 receptor agonist was associated with a 37% increased relative risk of gallbladder or biliary diseases (RR 1.37; 95% CI 1.23–1.52). The absolute risk difference was approximately 27 additional events per 10,000 patients per year.

This overall risk breaks down into specific conditions: cholelithiasis (gallstones) was increased by 27% (RR 1.27), cholecystitis (gallbladder inflammation) by 36% (RR 1.36), and biliary disease by 55% (RR 1.55). The cholecystectomy rate was increased by 70% (RR 1.70). Biliary cancer showed a directional increase that was not statistically significant (RR 1.43).

The risk was not uniform across populations. In trials specifically conducted for weight loss (where higher doses are used), the risk more than doubled: RR 2.29 (95% CI 1.64–3.18) compared with RR 1.27 in diabetes trials. This is consistent with the observation that both the medication itself and rapid weight loss independently contribute to gallstone formation.

A 2025 Frontiers in Pharmacology FAERS database analysis (Zhu et al.) examined real-world adverse event reports and confirmed the association. Semaglutide showed a reporting odds ratio (ROR) of 5.74 for cholecystitis and cholelithiasis, liraglutide showed an ROR of 6.75, and tirzepatide showed an ROR of 1.88. These real-world signals support the clinical trial findings and indicate the risk is not limited to controlled study conditions.

It is important to contextualize these numbers. A 37% relative risk increase sounds dramatic, but the absolute risk is 27 additional events per 10,000 patients per year. For most individuals, the risk of developing symptomatic gallbladder disease while on a GLP-1 remains low. The clinical question is not whether the risk exists, it does, but whether the benefits of GLP-1 therapy outweigh this risk for your specific situation.

Why GLP-1s increase gallstone risk: the mechanisms

The relationship between GLP-1 drugs and gallbladder disease is not simply "rapid weight loss causes gallstones." While weight loss itself is a known risk factor for gallstone formation, the evidence suggests GLP-1 medications contribute through multiple independent mechanisms.

The primary mechanism is suppression of cholecystokinin (CCK). GLP-1 receptor activation reduces postprandial CCK secretion, a hormone that normally triggers gallbladder contraction and bile release after meals. When CCK is suppressed, the gallbladder contracts less effectively, leading to bile stasis, bile that stays in the gallbladder for prolonged periods rather than being regularly emptied. This gives cholesterol crystals time to form, aggregate, and grow into stones.

A 2025 review in PMC (GLP-1 receptor agonists and gallbladder disease risk) described this pathway in detail: GLP-1RAs reduce CCK-dependent gallbladder contraction, disrupt FXR signaling (which regulates bile acid synthesis), alter TGR5 signaling (which affects cAMP-mediated gallbladder relaxation), and activate GLP-1 receptors in the nucleus tractus solitarius and area postrema, altering vagal nerve signaling to the gallbladder. These combined effects create a state of biliary stasis with prolonged bile retention and cholesterol supersaturation.

Rapid weight loss adds a second independent risk factor. When the body mobilizes fat stores rapidly, cholesterol is released into the bile, increasing the cholesterol saturation index. This supersaturated bile is more likely to precipitate into crystals. The combination of bile stasis (from CCK suppression) and cholesterol-supersaturated bile (from rapid fat mobilization) creates a synergistic stone-forming environment.

This is why the risk is highest in weight-loss trials using high doses: the drug suppresses gallbladder contraction while simultaneously driving the rapid fat loss that floods the bile with cholesterol. A 2024 study by Gameil et al. followed 308 patients with type 2 diabetes on GLP-1s for 12 months and found cholelithiasis in 31.2% of participants, with 60.4% of those developing symptoms. Liraglutide had the highest rate of symptomatic complicated cholelithiasis, followed by semaglutide.

The dose-dependency matters: lower doses used for diabetes control (semaglutide ≤0.5mg) did not show statistically significant gallbladder risk in the He et al. meta-analysis. The risk emerged at the higher doses used for weight management (semaglutide ≥1.0mg: RR 1.58). This suggests that the mechanism is pharmacologic, not merely a class effect, and that dose titration may be a relevant risk-management strategy.

Which GLP-1 drugs carry the highest gallbladder risk?

Not all GLP-1 drugs carry the same gallbladder risk. The He et al. meta-analysis reported drug-specific relative risks, and the differences are substantial enough to matter when choosing or continuing treatment:

Liraglutide (Saxenda, Victoza) carries the highest risk with an RR of 1.79 (95% CI 1.45–2.25). This aligns with earlier findings from the LEADER trial, which reported a hazard ratio of 1.60 for acute gallbladder disease with liraglutide compared with placebo. The Gameil et al. 2024 study found liraglutide had the highest rate of symptomatic complicated cholelithiasis among all GLP-1 drugs tested.

Semaglutide (Ozempic, Wegovy) shows a more nuanced picture. Overall, subcutaneous semaglutide was associated with an RR of 1.28 (95% CI 0.99–1.65), which was directional but did not reach statistical significance in the full analysis. However, when analyzed at higher doses (≥1.0mg weekly, the range used for weight management), the risk became significant: RR 1.58. The STEP 1 trial reported cholelithiasis in 1.5% of semaglutide 2.4mg participants versus 0.4% on placebo. Oral semaglutide (Rybelsus, the Ozempic pill) did not show an increased risk, though this may reflect the lower doses used in diabetes trials rather than a genuine pharmacologic difference.

Dulaglutide (Trulicity) showed an RR of 1.35 (95% CI 1.06–1.73), reaching statistical significance despite current prescribing information not containing gallbladder warnings. Exenatide (Byetta, Bydureon) showed an RR of 1.23 (95% CI 1.00–1.52), just below statistical significance.

Tirzepatide (Mounjaro, Zepbound) has a less well-characterized gallbladder risk profile. The SURMOUNT-1 trial reported cholelithiasis or cholecystitis in 1.4–1.8% of tirzepatide participants versus 0.5% on placebo, consistent with a modest elevation. The FAERS database analysis showed an ROR of 1.88, lower than semaglutide or liraglutide but still indicative of a signal. A 2024 meta-analysis by Zeng et al. found tirzepatide was significantly associated with the composite of gallbladder or biliary diseases, though the absolute risk appeared lower than for liraglutide or semaglutide.

A 2024 study comparing different GLP-1 RAs found that long-acting agents (semaglutide, dulaglutide) may exert a more pronounced inhibition of gallbladder contraction due to their extended half-lives, while short-acting agents (exenatide) have a milder impact. For patients with pre-existing gallbladder risk factors (older age, female sex, obesity, rapid weight loss history), choosing a short-acting agent or one with a lower gallbladder signal may be a reasonable consideration.

Gallbladder symptoms to watch for on GLP-1s

Gallbladder symptoms can be subtle or dramatic, and they are easy to mistake for the routine GI side effects of GLP-1 therapy. The key is knowing which symptoms are gallbladder-specific and when they warrant escalation.

The classic symptom of gallstones is biliary colic: a steady, severe pain in the right upper quadrant or epigastric area that may radiate to the right shoulder blade or back. It typically occurs 30–90 minutes after meals (especially fatty meals), lasts 30 minutes to several hours, and may be accompanied by nausea or vomiting. Between episodes, the person may feel completely normal.

On GLP-1s, the presentation can be trickier. Because GLP-1 drugs already suppress appetite and cause nausea, patients may dismiss gallbladder pain as "another bad nausea day" or "just the medication doing its thing." The distinguishing feature of gallbladder pain is its timing, it spikes after eating, not continuously. It also tends to localize to the right upper quadrant specifically, rather than generalized stomach discomfort.

Acute cholecystitis (gallbladder inflammation) presents with more severe symptoms: persistent right upper quadrant pain that does not resolve, fever, chills, tenderness when pressing on the upper right abdomen, and nausea or vomiting that may not improve. This is a medical emergency.

A 2024 cross-sectional study by Gameil et al. found that 60.4% of GLP-1 users who developed cholelithiasis during treatment became symptomatic, and 31.2% of those required clinical intervention. This is a higher symptomatic conversion rate than the general population, possibly because the CCK-suppression mechanism makes GLP-1-associated gallstones more likely to become symptomatic.

If you experience right upper quadrant pain that consistently follows meals, even if it resolves between episodes, it warrants a discussion with your prescriber or a primary care evaluation. A simple right upper quadrant ultrasound can confirm or rule out gallstones and guide the next steps.

How to reduce your gallbladder risk on GLP-1s

The good news: gallbladder risk on GLP-1s is partially modifiable. While you cannot eliminate the pharmacologic effect of CCK suppression, you can take several evidence-informed steps to reduce the likelihood of symptomatic gallstone formation:

Do not go zero-fat. This is the single most important and most commonly violated strategy. Your gallbladder needs dietary fat to contract and empty regularly. When you eat very low fat, your gallbladder does not get the signal to contract, and bile sits in the gallbladder for extended periods, exactly the condition that promotes stone formation. Aim for 20–30g of fat per day minimum, spread across meals. Healthy sources: avocado, olive oil, nuts, seeds, fatty fish, eggs. The starting-semaglutide guide recommends sesame oil, avocado, and egg fats, these are protective, not harmful.

Spread fat intake across the day rather than consuming it all in one meal. A little fat with each meal (5–10g) stimulates regular partial gallbladder emptying, keeping bile flowing instead of pooling. A single high-fat meal followed by days of very low fat creates an alternating pattern of gallbladder contraction followed by stasis, the worst of both worlds.

Avoid excessively rapid weight loss. Weight loss of more than 2 pounds (approximately 1 kg) per week has been associated with higher gallstone risk in the bariatric surgery literature, and the same principle applies to GLP-1 therapy. If you are losing weight faster than 2 lb per week consistently, discuss a dose adjustment with your prescriber. Slower, more gradual weight loss (1–2 lb per week) is safer for the gallbladder and equally effective for long-term outcomes.

Stay hydrated. Dehydration concentrates bile, increasing the cholesterol saturation index. Target 2.5–3 liters of fluid daily. Water, electrolyte drinks, and herbal teas all count.

Increase fiber gradually. Fiber binds cholesterol in the gut and reduces cholesterol absorption, which may lower biliary cholesterol saturation. However, a sudden large increase in fiber while on a GLP-1 can worsen bloating and constipation. Increase fiber intake slowly over 2–3 weeks. Good sources: oats, berries, chia seeds, leafy greens, cooked vegetables.

Consider ursodiol (ursodeoxycholic acid) for high-risk patients. In the bariatric surgery literature, ursodiol has been shown to reduce gallstone formation during rapid weight loss. Some prescribers offer it to GLP-1 patients with pre-existing gallbladder risk factors. This is a discussion with your clinician, not a self-treatment option.

The Gameil et al. algorithm published in the 2025 PMC review provides a clinical framework: for patients with pre-existing gallstones or sludge, consider pretreatment with ursodiol; for patients developing symptoms during therapy, evaluate with ultrasound and consider dose reduction or drug class switch; for patients with acute cholecystitis, standard surgical management with ERCP or cholecystectomy is appropriate.

When to seek medical care

Most gallbladder symptoms on GLP-1s are manageable and do not require emergency care. But some presentations do. The following symptoms warrant prompt medical evaluation:

Go to the emergency room if you experience: sharp, stabbing pain in the upper right abdomen that does not resolve after a few hours; pain that radiates to your back or right shoulder blade; fever or chills accompanying abdominal pain; nausea or vomiting that prevents you from keeping fluids down; jaundice (yellowing of the skin or eyes). These are signs of acute cholecystitis, choledocholithiasis (a stone lodged in the bile duct), or pancreatitis, all of which require immediate medical attention.

Contact your prescriber or schedule a same-week appointment if you experience: recurrent right upper quadrant pain after meals (even if it resolves between episodes); unexplained nausea that coincides with eating rather than being constant; a feeling of fullness or bloating in the upper right abdomen; or changes in stool color (pale or clay-colored stools suggest bile duct obstruction). A right upper quadrant ultrasound is the standard first test and is fast, non-invasive, and highly accurate for detecting gallstones.

It is important to distinguish gallbladder pain from pancreatitis, another serious but less common complication of GLP-1 therapy. Pancreatitis pain is typically severe, constant, located in the mid-epigastric or upper abdomen, and often radiates straight through to the back. It is usually accompanied by nausea, vomiting, and sometimes fever. The key difference: gallbladder pain is typically right-sided and episodic (comes and goes), while pancreatitis pain is central and constant. Both require prompt evaluation.

Life after gallbladder removal on GLP-1s

If gallstones become symptomatic and require intervention, the standard treatment is laparoscopic cholecystectomy (gallbladder removal). This is one of the most common surgeries performed worldwide, and the recovery is typically straightforward, most people return to normal activity within 1–2 weeks.

An important question for GLP-1 users: can I stay on my medication after gallbladder removal? The answer is generally yes. GLP-1 therapy can continue after cholecystectomy. The gallbladder itself is the site of stone formation, once it is removed, the stone-forming environment is eliminated. Bile will still flow from the liver directly into the small intestine (it no longer has a storage reservoir), but GLP-1 therapy does not interfere with this adapted physiology.

Some patients experience post-cholecystectomy diarrhea or bile acid malabsorption after gallbladder removal. This can be managed with dietary adjustments (smaller, more frequent meals; reduced fat per meal; bile acid sequestrants if needed). GLP-1 therapy may actually help in this context, since reduced appetite and slower gastric emptying can make post-surgery dietary adjustment easier.

If you are considering gallbladder surgery while on a GLP-1, the standard protocol is to hold the medication for one week before surgery due to the delayed gastric emptying effect, which increases aspiration risk during anesthesia. Your surgeon and anesthesiologist should coordinate this timing. After surgery, you can resume the medication once you are tolerating oral intake normally, typically within a few days to one week.

The bottom line

Gallbladder disease is a real and under-appreciated side effect of GLP-1 therapy. The evidence from 76 RCTs, real-world pharmacovigilance databases, and prospective cohort studies is consistent: GLP-1 use increases gallstone risk, especially at higher doses used for weight loss, and especially with certain drugs (liraglutide, high-dose semaglutide).

But the absolute risk is modest, approximately 27 additional events per 10,000 patients per year. For most people, the metabolic benefits of GLP-1 therapy (weight loss, glycemic control, cardiovascular protection) substantially outweigh the gallbladder risk. The goal is not to avoid GLP-1s because of gallbladder risk. It is to be aware of the risk, recognize symptoms early, and take the dietary steps that reduce the likelihood of developing symptomatic stones.

The most practical thing you can do: do not avoid fat. Your gallbladder needs 20–30g of dietary fat daily to contract and empty. The advice to eat low-fat on GLP-1s is misguided for gallbladder health, it actually increases stone risk by promoting bile stasis. Spread healthy fats across the day, lose weight at a moderate pace (1–2 lb per week), and stay hydrated. If you develop right upper quadrant pain that follows meals, get it checked with a simple ultrasound rather than dismissing it as routine nausea.

For protein tracking, symptom logging, and dose timing, all of which help you and your clinician monitor your GLP-1 journey, the OffRamp GLP-1 tracker is free and designed for this exact purpose.

Frequently asked questions

Can Ozempic or Wegovy cause gallstones?

Yes. A 2022 meta-analysis of 76 RCTs found that semaglutide use is associated with an increased risk of gallstones (RR 1.27 overall; RR 1.58 at doses ≥1.0mg used for weight loss). In the STEP 1 trial, cholelithiasis occurred in 1.5% of semaglutide 2.4mg users versus 0.4% on placebo. The absolute risk is modest, approximately 27 additional events per 10,000 patients per year, but it is a proven association.

Do all GLP-1 drugs have the same gallbladder risk?

No. Liraglutide carries the highest risk (RR 1.79). Semaglutide at weight-loss doses (≥1.0mg) shows elevated risk (RR 1.58). Dulaglutide (RR 1.35) and exenatide (RR 1.23) also show increased risk. Tirzepatide shows a modest elevation. Oral semaglutide has not shown an increased risk in clinical trials, though this may reflect the lower doses used in diabetes studies.

Is the gallbladder risk from GLP-1s just from rapid weight loss?

No. While rapid weight loss independently increases gallstone risk, GLP-1 drugs contribute through a separate mechanism: they suppress cholecystokinin (CCK), a hormone that triggers gallbladder contraction. This leads to bile stasis, bile sitting in the gallbladder for prolonged periods, which promotes cholesterol crystallization. The combination of CCK suppression and rapid fat mobilization creates a synergistic stone-forming environment.

What are the symptoms of GLP-1-related gallstones?

The classic symptom is biliary colic: steady, severe pain in the right upper abdomen that may radiate to the right shoulder blade or back, typically occurring 30-90 minutes after meals. On GLP-1s, symptoms can be mistaken for routine nausea. The distinguishing feature is timing, gallbladder pain spikes after eating and is right-sided, rather than being constant or generalized. Acute cholecystitis presents with persistent pain, fever, chills, and tenderness in the upper right abdomen.

Should I eat a low-fat diet on GLP-1s to protect my gallbladder?

No. This is a common misconception. Your gallbladder needs dietary fat (20-30g daily) to contract and empty regularly. Eating very low fat causes bile to sit in the gallbladder for extended periods, promoting stone formation. The key is to spread moderate amounts of healthy fat (avocado, olive oil, nuts, eggs, fatty fish) across meals throughout the day rather than avoiding fat entirely or eating it all at once.

How can I reduce my gallstone risk on GLP-1s?

Six evidence-backed strategies: (1) eat 20-30g of fat daily spread across meals, do not go zero-fat; (2) avoid losing weight faster than 2 lb per week, discuss dose reduction if losing too fast; (3) stay hydrated with 2.5-3L of fluid daily; (4) increase fiber gradually over 2-3 weeks; (5) get a right upper quadrant ultrasound if you develop post-meal right-sided pain; and (6) ask your prescriber about ursodiol if you have pre-existing gallbladder risk factors.

Can I continue GLP-1 therapy if I need gallbladder removal?

Yes. GLP-1 therapy can continue after cholecystectomy because the stone-forming environment (the gallbladder itself) has been removed. The medication should be held for one week before surgery due to aspiration risk from delayed gastric emptying. After surgery, once you are tolerating oral intake normally, you can resume the medication. Some patients experience post-cholecystectomy diarrhea, which is manageable with dietary adjustments.

When should I go to the ER for gallbladder symptoms on a GLP-1?

Go to the emergency room if you experience: sharp, stabbing pain in the upper right abdomen that does not resolve after a few hours; pain radiating to your back or right shoulder blade; fever or chills with abdominal pain; jaundice (yellowing of skin or eyes); or vomiting that prevents you from keeping fluids down. These can indicate acute cholecystitis, a bile duct stone, or pancreatitis, all requiring immediate medical attention.

Sources

This guide is grounded in the He et al. 2022 JAMA Internal Medicine meta-analysis (76 RCTs, 103,371 patients), the Zhu et al. 2025 FAERS database analysis (Frontiers in Pharmacology), the 2025 PMC review of molecular mechanisms of GLP-1-associated gallbladder disease (Gameil et al.), the Nreu et al. meta-analysis, the SURMOUNT-1 and STEP 1 trial safety data, and current prescribing information. Educational only, not a substitute for clinical advice.

Gallbladder disease is one of the most under-discussed side effects of GLP-1 therapy, but the evidence is consistent and actionable

Questions like "Can Ozempic cause gallstones?" and "Does Wegovy increase gallbladder risk?" are among the most common concerns users raise. The short answer: yes, but the risk is dose-dependent, drug-specific, and partially modifiable through dietary choices.

Track your GLP-1 journey free, symptoms, weight, protein, and dose timing →
This page is for general education only. It is not medical advice and should not replace care from your licensed healthcare provider.